GSDMD (gasdermin-D) promotes pyroptosis in response to microbial infection and danger signals. It is produced by the cleavage of gasdermin-D by inflammatory caspases CASP1 or CASP4 in response to canonical, as well as, non-canonical (such as cytosolic LPS) inflammasome activators. After cleavage, GSDMD moves to the plasma membrane where it strongly binds to inner leaflet lipids including phosphatidylinositol 4-phosphate, phosphatidylinositol (4,5)-biphosphate, phosphatidylinositol (3,4,5)-biphosphate, phosphatidic acid, and phosphatidylserine. GSDMD also exhibits bactericidal activity.

1810036L03Rik; DF 5L; DF5L; DFNA 5L; DFNA5L; FKSG 10; FKSG10; FLJ12150; Gasdermin D; Gasdermin domain containing 1; Gasdermin domain containing protein 1; Gasdermin domain-containing protein 1; Gasdermin-D; GasderminD; GSDMD; GSDMD_HUMAN; GSDMDC 1; GSDMDC1;

P57764

GSDMD Antibody detects endogenous levels of total GSDMD protein, including precursor and the cleaved N-terminal fragment.

Human, Mouse, Rat

Rabbit

53kD(full),35kD(cleaved);

Store at -20 °C. Stable for 12 months from date of receipt.

WB1:1000-1:2000；IF/IHC 1:100-1:1000

Western blot analysis of GSDMD using RAW 264.7 with 1 μg/mL lipopolysaccharides (LPS) for 4 h followed by 10 μM nigericin treatment under serum starved conditions for 2 h, whole cell lysate.